| Technical Name | 新冠肺炎病毒以及其變異株的單醣化棘突蛋白疫苗 | ||
|---|---|---|---|
| Project Operator | Academia Sinica | ||
| Project Host | 馬徹 | ||
| Summary | Monoglycosylated spike protein vaccine provides better protection against infections of SARS-CoV-2its variants of concern. Spike protein, which is the main immunogen in all current vaccines, is heavily glycosylatedthe epitopes covered by glycans are usually less immunogenic. Monoglycosylated spike protein vaccine, when vaccinated, can elicit better immune response with a more complete protection against all possible epitopes from spike polypeptide sequence,provide better protection against infections from variants of concerns. |
||
| Scientific Breakthrough | Compared to currently available COVID-19 vaccines, including mRNA, adenovirus, inactivated virusrecombinant protein, the monoglycosylated spike protein vaccine elicits better protection against infections of SARS-CoV-2its variants of concern. |
||
| Industrial Applicability | Vaccination of monoglycosylated spike vaccine elicits better protection against infections of SARS-CoV-2its variants of concern. |
||
| Matching Needs | 天使投資人、策略合作夥伴 |
||
| Keyword | SARS-CoV-2 COVID-19 Variants of concern Monoglycosylated spike vaccine | ||
| Notes | |||
- Contact
- cma@gate.sinica.edu.tw
other people also saw
